Literature DB >> 12925853

SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling.

David Wald1, Jinzhong Qin, Zhendong Zhao, Youcun Qian, Mayumi Naramura, Liping Tian, Jennifer Towne, John E Sims, George R Stark, Xiaoxia Li.   

Abstract

The Toll-like receptor-interleukin 1 receptor signaling (TLR-IL-1R) receptor superfamily is important in differentially recognizing pathogen products and eliciting appropriate immune responses. These receptors alter gene expression, mainly through the activation of nuclear factor-kappaB and activating protein 1. SIGIRR (single immunoglobulin IL-1R-related molecule), a member of this family that does not activate these factors, instead negatively modulates immune responses. Inflammation is enhanced in SIGIRR-deficient mice, as shown by their enhanced chemokine induction after IL-1 injection and reduced threshold for lethal endotoxin challenge. Cells from SIGIRR-deficient mice showed enhanced activation in response to either IL-1 or certain Toll ligands. Finally, biochemical analysis indicated that SIGIRR binds to the TLR-IL-1R signaling components in a ligand-dependent way. Our data show that SIGIRR functions as a biologically important modulator of TLR-IL-1R signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925853     DOI: 10.1038/ni968

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  197 in total

1.  Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Linda D Hazlett
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  The potential for Toll-like receptors to collaborate with other innate immune receptors.

Authors:  Subhankar Mukhopadhyay; Jurgen Herre; Gordon D Brown; Siamon Gordon
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

Review 3.  Highlights of the advances in basic immunology in 2011.

Authors:  Juan Liu; Shuxun Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2012-04-23       Impact factor: 11.530

4.  Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis.

Authors:  Javeed A Shah; Jay C Vary; Tran T H Chau; Nguyen D Bang; Nguyen T B Yen; Jeremy J Farrar; Sarah J Dunstan; Thomas R Hawn
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

5.  Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells.

Authors:  Julie M Davies; John MacSharry; Fergus Shanahan
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

6.  Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation.

Authors:  C Kadota; S Ishihara; M M Aziz; M A Rumi; N Oshima; Y Mishima; I Moriyama; T Yuki; Y Amano; Y Kinoshita
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

7.  Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.

Authors:  S K Drexler; J Wales; E Andreakos; P Kong; A Davis; C Garlanda; A Mantovani; T Hussell; M Feldmann; B M J Foxwell
Journal:  Scand J Immunol       Date:  2010-06       Impact factor: 3.487

8.  A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway.

Authors:  Emine Guven-Maiorov; Ozlem Keskin; Attila Gursoy; Ruth Nussinov
Journal:  Biophys J       Date:  2015-08-11       Impact factor: 4.033

9.  The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.

Authors:  Katarzyna Bulek; Shadi Swaidani; Jinzhong Qin; Yi Lu; Muhammet F Gulen; Tomasz Herjan; Booki Min; Robert A Kastelein; Mark Aronica; Magdalena Kosz-Vnenchak; Xiaoxia Li
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 10.  IL-37: An anti-inflammatory cytokine with antitumor functions.

Authors:  Yu Mei; Haiyan Liu
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.